Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]
News [5245]
Articles [128]
Editorials [4]
Conferences [157]
elearning [13]
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA...
Prof Hope Rugo - University of California, San Francisco, USA
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
12 Jun 2019
Advances in PARP inhibitor use for metastatic breast cancer
Prof Hope Rugo - University of California, San Francisco, USA
Advances in PARP inhibitor use for metastatic breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
12 Jun 2019
The future of PARP inhibitors in metastatic breast cancer
Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...
The future of PARP inhibitors in metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )
12 Jun 2019
A phase II study of bemcentinib with pembrolizumab in patients with advanced...
Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC ( Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
11 Jun 2019
Ribociclib plus endocrine therapy improves survival in premenopausal patients...
Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...
Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Jun 2019
Managing metastatic breast cancer and beyond using PARP inhibitors
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
Updates in metastatic and early-stage breast cancer
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
11 Jun 2019
PARP inhibitors in metastatic breast cancer: Where are we now?
Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany
PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )
11 Jun 2019
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor...
Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies ( Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands )
10 Jun 2019
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG...
Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )
10 Jun 2019
Genetic testing and PARP inhibitors in metastatic prostate cancer
Dr Neal Shore and Dr Joaquin Mateo
Genetic testing and PARP inhibitors in metastatic prostate cancer ( Dr Neal Shore and Dr Joaquin Mateo )
7 Jun 2019
Breast cancer highlights from ASCO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ASCO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
6 Jun 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation